Core Viewpoint - The financing balance of the ChiNext market has decreased for four consecutive trading days, totaling a reduction of 2.429 billion yuan during this period [1][2]. Financing Balance Overview - As of April 29, 2025, the total margin balance of the ChiNext market is 336.055 billion yuan, a decrease of 0.335 billion yuan from the previous trading day [1][2]. - The financing balance specifically is 335.193 billion yuan, down by 0.330 billion yuan from the previous day [1][2]. Individual Stock Performance - During the decline in financing balance, 383 stocks saw an increase in financing balance, with 28 stocks increasing by over 20% [2]. - The stock with the highest increase in financing balance is Bochuang Technology, which rose by 87.43% to 19.886 million yuan [3]. - Conversely, 554 stocks experienced a decrease in financing balance, with 57 stocks declining by over 10% [2]. - The largest decrease was seen in Jusa Long, which fell by 29.74% to 7.20976 million yuan [3]. Sector Analysis - Stocks with financing balance increases exceeding 20% are primarily concentrated in the pharmaceutical, electrical equipment, and automotive sectors, with 5, 4, and 4 stocks respectively [4]. Market Performance - Stocks with financing balance increases over 20% averaged a rise of 3.61%, outperforming the ChiNext index [5]. - Notable gainers include United Chemical, Bochuang Technology, and Weike Technology, with increases of 63.58%, 26.60%, and 19.55% respectively [5]. - Significant decreases were observed in Mango Super Media, Honggong Technology, and Hunan Yunan, with declines of 16.32%, 15.60%, and 12.39% respectively [5]. Financing Balance Changes - The stock with the largest increase in financing balance is Xinyi Sheng, with a total of 3.365 billion yuan, increasing by 195 million yuan [5]. - The stocks with the largest decreases include Dongfang Caifu, Shenghong Technology, and Runze Technology, with reductions of 5.33 billion yuan, 3.62 billion yuan, and 2.04 billion yuan respectively [5].

Group 1: Company Insights - The company achieved a revenue of 11.36 billion yuan in Q1 2025, representing a year-on-year increase of 22.47% and a quarter-on-quarter increase of 29.43% [5] - The net profit attributable to shareholders for Q1 2025 was 2.83 billion yuan, up 11.82% year-on-year, while the non-recurring net profit was 2.75 billion yuan, reflecting a year-on-year increase of 38.71% [5] - The newly launched game "Wanjian Changsheng" contributed significantly to revenue and profit growth in Q1 2025, with a revenue of 3.63 billion yuan [6] Group 2: Industry Trends - The eye care industry is experiencing a slowdown in growth, with the company managing to maintain revenue growth despite external challenges, achieving a revenue of 60 billion yuan in Q1 2025, up 16% year-on-year [8][9] - The company is expanding its international presence, with significant revenue contributions from Europe and Southeast Asia, achieving a total revenue of 210 billion yuan in 2024 [10] - The chemical industry is seeing a substantial increase in revenue, with the company reporting a revenue of 8.59 billion yuan in Q1 2025, a year-on-year increase of 91.68% [12][15] Group 3: Financial Performance - The company reported a net profit of 0.67 billion yuan in Q1 2025, which is a 10.46% increase year-on-year and a remarkable 902.93% increase quarter-on-quarter [12][15] - The net profit margin for the company improved significantly, with a sales net profit margin of 10.80% in Q1 2025, reflecting a year-on-year decrease of 3.1 percentage points [12] - The company is expected to see continued revenue growth, with projected revenues of 41.27 billion yuan, 48.48 billion yuan, and 55.70 billion yuan for 2025, 2026, and 2027 respectively [17]

每经记者 郑步春 每经编辑 彭水萍 继周一普跌后，周二A股稍有反弹，消息面暂显平淡。截至收盘，上证综指微跌0.05%至3286.65点。其 余各主要股指普涨，深综指涨0.24%，创业板综指涨0.5%，科创50指数涨0.1%，北证50指数涨1.23%。 全A总成交额为10418亿元，较周一的10768亿元进一步萎缩。 汇市方面，美元于本周有所下跌，但周二于亚欧交易时段已有所反弹。整体而言，近几个交易日美元表 现应该算是比较平稳。人民币汇率近两周呈震荡盘升格局，周一人民币汇率升势有所加快，至周二傍晚 时分，离岸人民币汇率已升至7.26左右。 本周以来的两个交易日A股整体表现稍稍偏弱，成交量也一缩再缩，暗示投资者已经减少了做多操作。 市场做多情绪之所以暂不太积极，应部分与近期消息面暂无特别明显的利好相关。 虽然上周五的重大会议释出了不少积极信号，但股市投资者十分在意的与"增加财政刺激规模"的内容暂 缺，这至少会对预期过于乐观的投资者情绪构成些打击。大家知道，在会议召开之前，市场对宽松政策 大幅加码的确是存在些预期的，所以最终消息与预期或多或少应存在些落差。 在外部因素方面，中美关税摩擦即使已有缓和迹象，但美国那边的 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [3][5][18]. Core Views - The company's revenue and net profit for the first quarter of 2025 showed significant year-on-year and quarter-on-quarter growth, with revenue reaching 4.299 billion yuan, a year-on-year increase of 22.99% and a quarter-on-quarter increase of 3.38%. The net profit attributable to shareholders was 465 million yuan, up 67.85% year-on-year and 131.19% quarter-on-quarter [1][7]. - The growth in the company's methionine business, which saw a 29% year-on-year increase in sales revenue, was driven by a 24% increase in liquid methionine sales volume and price increases implemented during the quarter [2][10]. - The company is implementing a "dual pillar" strategy, with steady growth in specialty products, which saw a 7% increase in revenue and a 5% increase in gross profit [2][17]. Summary by Sections Financial Performance - In Q1 2025, the company's gross profit increased by 14% to 1.27 billion yuan, with functional product sales revenue growing by 29% and specialty product sales revenue increasing by 7% [1][7]. - The gross margin for sales was 29.64%, a year-on-year decrease of 2.32 percentage points but a quarter-on-quarter increase of 0.43 percentage points. The net profit margin was 10.82%, up 2.90 percentage points year-on-year and 5.96 percentage points quarter-on-quarter [1][7]. Business Segments - The methionine segment's sales revenue grew by 29% year-on-year, supported by price increases and high production capacity utilization, which mitigated the impact of rising raw material costs [2][10]. - The vitamin segment performed well, with strong sales growth despite price pressures on vitamin A and robust demand for vitamin E [2][15]. - Specialty products showed stable growth, with notable increases in sales from specific product lines, including a 21% increase in selenium products and a 24% increase in palatability products [2][17]. Profit Forecasts - The company is expected to achieve net profits of 1.625 billion yuan, 1.795 billion yuan, and 2.040 billion yuan for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 35.0%, 10.4%, and 13.6% [3][18].

Investment Rating - The report maintains an "Outperform the Market" rating for the company [4][20][6] Core Views - The company's first-quarter net profit reached a historical high, with a revenue of 5.44 billion yuan, representing a year-on-year growth of 20.91% and a net profit of 1.88 billion yuan, up 116.18% year-on-year [1][9] - The profitability is supported by a decrease in expense ratios and a sustained high level of R&D investment, with a gross margin of 46.70% and a net margin of 34.70% in the first quarter [1][9] - The methionine market is experiencing price increases, with the average price in 2024 rising by 14.01% compared to 2023, positively impacting the company's performance [2][11] - The company is expanding its production capacity, with a total methionine capacity expected to reach 460,000 tons per year, positioning it as the third-largest globally [2][16] Financial Performance - The company achieved a net profit of 1.88 billion yuan in Q1 2025, with a year-on-year growth of 116.18% and a slight quarter-on-quarter increase of 0.05% [1][9] - The R&D expense ratio was 4.72%, indicating a commitment to innovation and development [1][9] - The forecasted net profits for 2025-2027 are 6.49 billion, 7.09 billion, and 7.62 billion yuan respectively, with corresponding earnings per share of 2.11, 2.31, and 2.48 yuan [4][20] Market Trends - The prices of vitamins A and E are under pressure, while vitamin D3 prices are on the rise, contributing to the overall performance of the company [3][18] - The methionine market is expected to continue benefiting from rising prices and increased production capacity, supporting the company's growth trajectory [2][16]

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company reported better-than-expected performance in Q4 2024, with a focus on optimizing the supply chain for its plant protection business [5][6]. - The company's revenue for 2024 was 5.68 billion yuan, a decrease of 11.88% year-on-year, but it achieved a net profit of 103 million yuan, marking a return to profitability [5][6]. - The plant protection business experienced a revenue decline due to falling pesticide prices, but gross margins improved due to technological innovation and management optimization [6][7]. - The company is expanding its supply chain layout with a new production base in Malaysia, enhancing its service offerings across the product lifecycle [7]. Summary by Sections Financial Performance - In Q4 2024, the company achieved a revenue of 1.32 billion yuan, down 7.44% year-on-year, but net profit reached 70.64 million yuan, a significant increase of 285% quarter-on-quarter [5]. - For Q1 2025, revenue was 1.51 billion yuan, up 3.02% year-on-year and 14.55% quarter-on-quarter, with a net profit of 49.72 million yuan, reflecting a year-on-year growth of 1747% [5]. Business Segments - The pharmaceutical segment generated 1.29 billion yuan in revenue, down 13.3% year-on-year, but gross margin improved by 13.1 percentage points to 48.0% [6]. - The plant protection segment had a revenue of 3.59 billion yuan, down 15.4% year-on-year, with a gross margin increase of 5.8 percentage points to 20.1% [6]. Future Outlook - The company has revised its profit forecasts for 2025-2027, expecting net profits of 305 million yuan, 415 million yuan, and 536 million yuan respectively, reflecting a positive outlook based on industry recovery and improved margins [8][9]. - The report highlights the company's ongoing projects in the pharmaceutical sector, including six validation projects, with a focus on API and innovative drug intermediates [7][8].

前十大流通股东累计持有： 4905.35万股，累计占流通股比： 55.78%，较上期变化： 18.52万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 朱学军 | 2191.27 | 24.92 | 不变 | | 崔小丽 | 921.77 | 10.48 | 不变 | | 朱萌 | 891.59 | 10.14 | 不变 | | 尤卫民 | 251.75 | 2.86 | 不变 | | 董敏 | 141.20 | 1.61 | 17.80 | | 赵贯云 | 128.66 | 1.46 | 37.54 | | 王芳 | 108.17 | 1.23 | 1.78 | | 夏勇 | 98.00 | 1.11 | -22.35 | | 黄剑斌 | 86.93 | 0.99 | 新进 | | 张文泉 | 86.01 | 0.98 | 不变 | | | 较上个报告期退出前十大股东有 | | | | 广发多因子混合 | 103.18 | 1.17 | 退出 | 三、分红送配方案情况 一、主要会计数据和财务指标 | 报告期指标 ...

投资者关系活动记录表 编号：2025-001 投资者关系活 动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 参与单位名称 及人员姓名 投资者网上提问 时间 2025 年 4 月 29 日 (周四) 下午 13:00~17:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用 网络远程的方式召开业绩说明会 上市公司接待 人员姓名 1、董事兼副总经理兼董事会秘书王丽 2、财务总监罗梅 3、独立董事陈清胜 4、董事长兼总经理严建林 投资者关系活 动主要内容介 绍 本次投资者关系活动以线上方式进行，公司高管与投资者进行了 沟通交流，主要内容如下： 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、股权转让进度 投资者你好，公司实际控制人协议转让股份事宜正在办理过 户登记手续，公司将根据进展情况及时履行信息披露义务， 感谢关注。 2、贵公司和安利股份比较有什么异同，主要优势有哪些 投资者你好，安利股份系公司合成革用聚氨酯材料的潜在客 证券代码：300535 证券简称：达威股份 四川达威科技股份有限公 ...

前十大流通股东累计持有： 8892.86万股，累计占流通股比： 25.8%，较上期变化： -1196.94万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.7300 | 0.8700 | -16.09 | 1.2400 | | 每股净资产（元） | 8.17 | 7.63 | 7.08 | 10.44 | | 每股公积金(元) | 3.34 | 3.54 | -5.65 | 5.58 | | 每股未分配利润(元) | 3.40 | 3.05 | 11.48 | 3.46 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 14.48 | 14.04 | 3.13 | 18.42 | | 净利润(亿元) | 2.5 | 2.97 | -15.82 | 4.24 | | 净资产收益率(%) | 8.96 | 11.62 | -22.89 | 18.71 | 数据四舍五入，查看更多财务数据> ...

2025 年 4 月 29 日 当前价：16.43 元 作者 分析师：赵乃迪 执业证书编号：S0930517050005 010-57378026 zhaond@ebscn.com 分析师：周家诺 执业证书编号：S0930523070007 021-52523675 zhoujianuo@ebscn.com 公司研究 资产减值影响 24Q4 业绩，龙南基地项目陆续投产 ——广信材料（300537.SZ）2024 年报及 2025 一季报点评 增持（维持） 市场数据 | 总股本(亿股) | 2.00 | | --- | --- | | 总市值(亿元)： | 32.93 | | 一年最低/最高(元)： | 14.00/24.83 | | 近 3 月换手率： | 318.54% | 股价相对走势 -10% 11% 33% 54% 75% 04/24 07/24 10/24 01/25 广信材料 沪深300 收益表现 | % | 1M | 3M | 1Y | | --- | --- | --- | --- | | 相对 | -7.50 | -1.26 | 4.03 | | 绝对 | -10.22 | -1.62 | ...